Publications by authors named "Stephen Ruberg"

Claim this Profile
E
Estimand Endpoints for Longitudinal Measures of Continuous Disease Progression with an Alzheimer's Disease Example.
Haoyan Hu, Miroslaw Brys, Stephen J Ruberg, Yongming Qu

Ther Innov Regul Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors.
Konstantinos Sechidis, Sophie Sun, Yao Chen, Jiarui Lu, Cong Zhang, Stephen Ruberg

Pharm Stat· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to 'Bayesian approaches in drug development: continuing the virtuous cycle'.
Stephen J Ruberg

Nat Rev Drug Discov· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A platform for comparing subgroup identification methodologies.
Stephen Ruberg, Ying Zhang, Hollins Showalter, Lei Shen

Biom J· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CITIES: Clinical trials with intercurrent events simulator.
Ahmad Hakeem Abdul Wahab, Yongming Qu, Hege Michiels, Junxiang Luo, Run Zhuang, Stephen Ruberg

Biom J· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical Trials.
Yongming Qu, Robin D White, Stephen J Ruberg

Ther Innov Regul Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Bayesian approaches in drug development: starting a virtuous cycle.
Stephen J Ruberg, Francois Beckers, Rob Hemmings, Peter Honig, Telba Irony

Nat Rev Drug Discov· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the treatment effect for adherers using multiple imputation.
Junxiang Luo, Stephen J Ruberg, Yongming Qu

Pharm Stat· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysis.
Mark Rothmann, William Crown, Thomas A Louis, Thomas Permutt, Stephen Ruberg

Pharm Stat· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: The hardest problem there is.
Stephen J Ruberg

Pharm Stat· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Détente: A Practical Understanding of P values and Bayesian Posterior Probabilities.
Stephen J Ruberg

Clin Pharmacol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of tripartite estimands using adherence causal estimators under the causal inference framework.
Yongming Qu, Junxiang Luo, Stephen J Ruberg

Pharm Stat· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD.
Oliver N Keene, Stephen Ruberg, Alexander Schacht, Mouna Akacha, Rachael Lawrance

Pharm Stat· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.
Lu Tian, Haoda Fu, Stephen J Ruberg, Hajime Uno, Lee-Jen Wei

Biometrics· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Evaluating Treatment Effects From Randomized Clinical Trials.
Stephen J Ruberg, Mouna Akacha

Clin Pharmacol Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimands in clinical trials - broadening the perspective.
Mouna Akacha, Frank Bretz, Stephen Ruberg

Stat Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making what's advanced today routine tomorrow.
Stephen J Ruberg

J Biopharm Stat· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity.
Stacy R Lindborg, Charles C Persinger, Andreas Sashegyi, Craig Mallinckrodt, Stephen J Ruberg

Nat Rev Drug Discov· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying potential adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison models.
Haoda Fu, Karen L Price, Mary E Nilsson, Stephen J Ruberg

J Biopharm Stat· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A portfolio-based approach to optimize proof-of-concept clinical trials.
Craig Mallinckrodt, Geert Molenberghs, Charles Persinger, Stephen Ruberg, Andreas Sashegyi

J Biopharm Stat· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early improvement in pain predicts pain response at endpoint in patients with fibromyalgia.
Fujun Wang, Stephen J Ruberg, Paula J Gaynor, Alexandra N Heinloth, Lesley M Arnold

J Pain· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup identification from randomized clinical trial data.
Jared C Foster, Jeremy M G Taylor, Stephen J Ruberg

Stat Med· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
Stephen J Ruberg, Lei Chen, Virginia Stauffer, Haya Ascher-Svanum, Sara Kollack-Walker

BMC Psychiatry· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mean does not mean as much anymore: finding sub-groups for tailored therapeutics.
Stephen J Ruberg, Lei Chen, Yanping Wang

Clin Trials· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients.
Stan L Block, David Williams, Craig L Donnelly, David W Dunn, Keith E Saylor, Stephen J Ruberg

Clin Pediatr (Phila)· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis